JGUA
DGX icon

John G. Ullman & Associates’s Quest Diagnostics DGX Stock Holding History

John G. Ullman & Associates’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$398K Buy
2,032
+100
+5% +$19.4K 0.05% 141
2025
Q4 		$335K Buy
1,932
+818
+73% +$149K 0.04% 151
2025
Q3 		$212K Hold
1,114
– – 0.03% 164
2025
Q2 		$200K Buy
+1,114
New +$193K 0.03% 170
2021
Q3 		– Sell
-1,784
Closed -$235K – 163
2021
Q2 		$235K Sell
1,784
-29,318
-94% -$3.84M 0.03% 147
2021
Q1 		$3.99M Sell
31,102
-14,524
-32% -$1.79M 0.54% 49
2020
Q4 		$5.44M Sell
45,626
-300
-0.7% -$36.6K 0.84% 43
2020
Q3 		$5.26M Sell
45,926
-700
-2% -$82.7K 1.09% 35
2020
Q2 		$5.31M Sell
46,626
-110
-0.2% -$11.7K 1.3% 27
2020
Q1 		$3.75M Sell
46,736
-50
-0.1% -$5.18K 1% 31
2019
Q4 		$5M Sell
46,786
-650
-1% -$67.8K 0.86% 38
2019
Q3 		$5.08M Sell
47,436
-50
-0.1% -$5.13K 0.92% 36
2019
Q2 		$4.83M Sell
47,486
-360
-0.8% -$34.6K 0.85% 37
2019
Q1 		$4.3M Buy
47,846
+350
+0.7% +$30.3K 0.78% 41
2018
Q4 		$3.96M Sell
47,496
-200
-0.4% -$18.8K 0.8% 35
2018
Q3 		$5.15M Sell
47,696
-323
-0.7% -$35.4K 0.94% 36
2018
Q2 		$5.28M Sell
48,019
-280
-0.6% -$29.2K 1% 37
2018
Q1 		$4.84M Sell
48,299
-70
-0.1% -$7.17K 0.94% 37
2017
Q4 		$4.76M Sell
48,369
-374
-0.8% -$35.5K 0.95% 35
2017
Q3 		$4.56M Sell
48,743
-796
-2% -$84.5K 0.89% 42
2017
Q2 		$5.51M Sell
49,539
-910
-2% -$96.2K 1.09% 37
2017
Q1 		$4.95M Sell
50,449
-800
-2% -$76.3K 1.02% 38
2016
Q4 		$4.71M Buy
51,249
+2,263
+5% +$195K 0.99% 38
2016
Q3 		$4.15M Sell
48,986
-1,000
-2% -$84K 0.85% 42
2016
Q2 		$4.07M Buy
49,986
+46
+0.1% +$3.5K 0.84% 43
2016
Q1 		$3.57M Buy
49,940
+11,764
+31% +$789K 0.84% 38
2015
Q4 		$2.72M Buy
38,176
+2,350
+7% +$158K 0.6% 50
2015
Q3 		$2.2M Buy
35,826
+31,600
+748% +$2.21M 0.52% 56
2015
Q2 		$306K Buy
4,226
+236
+6% +$17.4K 0.06% 122
2015
Q1 		$307K Hold
3,990
– – 0.06% 121
2014
Q4 		$268K Hold
3,990
– – 0.05% 130
2014
Q3 		$242K Sell
3,990
-210
-5% -$12.9K 0.05% 132
2014
Q2 		$246K Hold
4,200
– – 0.04% 137
2014
Q1 		$243K Buy
+4,200
New +$225K 0.05% 132
2013
Q4 		– Sell
-3,636
Closed -$225K – 152
2013
Q3 		$225K Sell
3,636
-300
-8% -$18K 0.05% 141
2013
Q2 		$239K Buy
+3,936
New +$234K 0.05% 140

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

John G. Ullman & Associates's DGX Position: Q1 2026 in Review

John G. Ullman & Associates increased its Quest Diagnostics (DGX) stake by 5.2% in Q1 2026, buying an estimated $19.4K and bringing the position to 2,032 shares worth $398K. The position accounts for 0.05% of the portfolio, ranked #141.

John G. Ullman & Associates first reported a position in DGX in Q2 2013 and has held it in 36 quarters since. The position peaked at $5.51M in Q2 2017. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • John G. Ullman & Associates held 2,032 shares of Quest Diagnostics worth $398K as of Q1 2026.
  • John G. Ullman & Associates bought 100 Quest Diagnostics shares in Q1 2026, an estimated $19.4K.
  • Quest Diagnostics made up 0.05% of John G. Ullman & Associates's portfolio in Q1 2026, its #141 holding.
  • John G. Ullman & Associates first reported a position in Quest Diagnostics in Q2 2013 and has held it in 36 quarters since.
  • John G. Ullman & Associates's Quest Diagnostics position peaked at $5.51M in Q2 2017.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on John G. Ullman & Associates's 13F filing for Q1 2026, filed 6 May 2026.